INOHealthcare · BiotechnologyThe 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. hold a median 12-month price target of $3 — +288.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Inovio Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (74): Analysts have, on balance, been raising their forecasts.
Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on INO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +288.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Jefferies | Upgrade | Buy | $1.80 → $3.00 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $6.00 → $4.00 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Neutral | $3.00 → $2.50 |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 14 Nov 2025 | Piper Sandler | Reiterates | Overweight | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 July 2025 | Piper Sandler | Initiates | Overweight | — |
| 14 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 14 May 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 19 Mar 2025 | RBC Capital | Maintains | Sector Perform | — |
| 14 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | $18 |
| 13 Jan 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 10 Jan 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 18 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 18 Nov 2024 | Oppenheimer | Maintains | Outperform | — |
| 15 Nov 2024 | RBC Capital | Maintains | Sector Perform | — |
| 4 Oct 2024 | RBC Capital | Maintains | Sector Perform | $8.00 → $7.00 |
| 12 Aug 2024 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
INO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Inovio Pharmaceuticals, Inc. returned −68.2% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 1% of US stocks
Cheaper than 5% of US stocks
Cheaper than 68% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Inovio Pharmaceuticals, Inc. has a market value of $92.0M and an enterprise value of $63.4M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$84.9M.
Free cash flow in the twelve months to 31 Mar 2026: −$83.6M, after $226K of capital spending.
Trailing P/E: −0.5×; forward P/E: −2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Inovio Pharmaceuticals, Inc. employs 112 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Inovio Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
INOVIO announced that it secured a judgment of $80,416,101 on all claims it filed against VGXI, Inc. and GeneOne Life Science, Inc.
Why it matters — The judgment is a material litigation outcome involving INOVIO and the two defendants.
Zacks Investment Research published an article highlighting four top-ranked stocks with rising P/E ratios as part of an out-of-the-box investment approach. The piece presents this strategy without focusing specifically on Inovio Pharmaceuticals.
Why it matters — An INO watcher would want to know whether Inovio is among the four stocks cited in this coverage, as such mentions can influence investor attention.
Inovio Pharmaceuticals presented prepared remarks at the H.C. Wainwright 28th Annual Global Investment Conference. A transcript of these remarks has been published on Seeking Alpha.
Why it matters — The prepared remarks offer INO watchers a direct account of what the company communicated to investors at a major industry conference.
Inovio Pharmaceuticals announced that its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, remains under FDA review with a target action date of Oct. 30.
Why it matters — The upcoming PDUFA date is a key regulatory milestone for INO-3107, and its FDA decision could significantly affect Inovio's outlook.
Inovio Pharmaceuticals is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis (RRP), as disclosed by President and CEO Jacky Shea during a Cantor Fitzgerald fireside chat.
Why it matters — The upcoming FDA decision date for INO-3107 marks a key regulatory milestone for Inovio's lead candidate in RRP.
The 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. have a median 12-month price target of $3, with estimates ranging from $2.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Inovio Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inovio Pharmaceuticals, Inc. 51 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Inovio Pharmaceuticals, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (74 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +288.7% from the last close, and Ticker Nerd's factor model ranks Inovio Pharmaceuticals, Inc. 51 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Inovio Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $4 over the next 12 months.
Inovio Pharmaceuticals, Inc. returned -68.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases.
The most recent item we track (PRNewsWire, 20 Oct 2026): "INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science". INOVIO announced that it secured a judgment of $80,416,101 on all claims it filed against VGXI, Inc. and GeneOne Life Science, Inc.
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.
CEO Dr. Jacqueline E. Shea Ph.D. · 112 employees · United States · https://www.inovio.com
